Open AccessRhabdomyolysis in a patient under treatment with sorafenib
Author(s) -
M.M. Díaz Alcázar,
Eloísa Cervilla Sáez de Tejada,
E. Ruiz Escolano
Publication year - 2020
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2020.6440/2019
Subject(s) - medicine , rhabdomyolysis , sorafenib , intensive care medicine , hepatocellular carcinoma
We present a case of rhabdomyolysis related to treatment with sorafenib in a patient with multifocal hepatocellular carcinoma. Rhabdomyolysis is a severe situation and potentially fatal. There are no laboratory data that can predict this condition. Early diagnosis is essential for prognosis. Rhabdomyolysis has been described as an adverse reaction of several drugs but it is not frequently related to sorafenib.